Andrew Pollard

Professor Andrew Pollard
Born	29 August 1965 Tunbridge Wells, England, UK
Alma mater	GKT School of Medical Education, Queen Mary University of London
Leader of the Oxford Vaccine Group, the creator of the AstraZeneca Covid jab  Oxford Vaccine Group/Director In office 2001 - Present

This page includes chunks of 3rd party text that are not marked as such with quote marks.

Andrew Pollard is a British medical manager. Since 2001, he has been the leader of the Oxford Vaccine Group, the (alleged) creator in 2020 of the AstraZeneca Covid jab.

Education

He attended Guy's Hospital Medical School graduating with a BSc in 1986, and subsequently obtained an Bachelor of Medicine, Bachelor of Surgery from the University of London (1989) at St Bartholomew's Hospital Medical School. After house jobs at Barts and Whipps Cross Hospital and working as an A&E senior house officer at the Whittington Hospital, London, he trained in Paediatrics at Birmingham Children's Hospital, UK, specialising in Paediatric Infectious Diseases at St Mary's Hospital, London, and at British Columbia Children's Hospital, Vancouver. He obtained his PhD at St Mary's Hospital, from the University of London in 1999.

OVG Director

In 2001 Andrew Pollard was appointed Director of the Oxford Vaccine Group, which comprises around 75 members across a number of disciplines, including consultants in paediatrics and vaccinology, clinical research fellows, research nurses, statisticians, post-doctoral laboratory scientists, research assistants and DPhil students.

JCVI Chair

OVG’s Director, Andrew Pollard, is ^[When?] concurrently Senior Advisor to the Medicines and Healthcare Products Regulatory Agency (MHRA) Panel, advises the European Medicine Agency (EMA) and chairs the Joint Committee on Vaccination and Immunisation (JCVI).

Facebook critique

On 21 May 2020, Liz Watkins Barton reported on Facebook:

One day after revelations that the Gates/Fauci Moderna vax caused severe illnesses in 20% of high-dose recipients, Bill Gates got devastating news about his other “warp-speed” COVAX bet.

The Oxford Vaccine Group (OVG) spiked-protein vaccine was on an even faster track than Moderna. In May, Melinda Gates predicted it would be jab-ready by years’ end. Oxford and UK officials promised 30 million doses by September

On April 24, OVG scientists announced that macaque studies proved the vaccine effective. OVG quickly recruited 510 healthy volunteers for human trials. Raw data released this week reveal the OVG team was lying.

All vaccinated macaques sickened after exposure to COVID-19. Edinburgh University’s Eleanor Riley told Forbes the vax provided ‘insufficient’ antibodies to prevent infection and viral shedding. Vaxxed monkeys spread the disease as readily as unvaccinated.

The OVG is politically wired. Lead developer, Andrew Pollard juggles scandalous conflicts that allow him to license, register, + mandate his own untested vaccines to the masses. Pollard’s political contacts won him $110 million in government grants for his jab. Pollard is Senior Advisor to Britain’s MHRA Panel which licenses vaccines, chairs Britain’s JCVI committee that mandates them + advises the European Medicine Agency (EMA) He takes payments from virtually all the big vax makers.

In 2014, Pollard developed GlaxoSmithKline’s notorious Bexero Meningitis vax, and then mandated it to children precipitating a Kawasaki disease epidemic. The package insert says Bexero may cause Kawasaki in 3 out of every 1000 children.

Pollard used his power and deceitful puffery about the monkey trial to prematurely bulldoze his COVID-19/Vaccine into human trials. He shunned placebo tests + restricted safety studies to a tight timeline to hide long-term injuries. He included only super healthy people while planning to roll out his vaccine to vulnerable children with chronic co-morbidities and fragile elders.

Pollard, is steaming ahead with his ineffective vaccine. He claims that it might make symptoms milder. But a vaccine that hides symptoms + allows transmission is worse than no vaccine at all.

"Bird flu"

In December 2024, Pollard, director of the Oxford Vaccine Group, defended the government's purchase of five million doses of "vaccine" against "bird flu: "Emergence of a new strain of influenza remains at the top of the list of pandemic threats and so providing resilience against potential risky flu types, like H5, is important for future pandemic and outbreak preparedness."

Many thanks to our Patrons who cover ~2/3 of our hosting bill. Please join them if you can.